Delivering Market Success For Pharma Partners From Concept To Patient

By Shari Krusniak, Director, Services marketing strategy, and Patrick McLoughlin, Sr. Director, Strategic Programs, CM and Devices

With the biologics and biosimilar markets projected to grow rapidly, pharmaceutical companies will face challenges in protecting their intellectual property and market share. The development of these products is complex and expensive, and there is a shift towards at-home care, necessitating innovative and patient-friendly drug delivery devices.

The processes involved in developing market-ready therapies include extensive research, clinical trials, regulatory approvals, and manufacturing practices. These therapies then undergo rigorous testing through preclinical and clinical trials to assess their safety and efficacy. Regulatory approvals are crucial to ensure the therapies meet safety and efficacy standards, while manufacturing practices play a vital role in producing consistent and high-quality therapies.

Pharmaceutical companies rely on their partners to continuously improve and innovate drug delivery platforms. Open communication, real-time data access, and flexibility are essential in partnerships to adapt to market changes and provide vendor-managed inventory.

This article highlights the importance of developing complex and user-friendly drug delivery systems that integrate seamlessly into a patient's life. Understand the need for discreet, frictionless, and user-friendly systems that improve adherence and simplify the delivery process.